To investigate the contribution of IL-1, IL-6, and TNF to the increased osteoclastogenesis induced by estrogen deficiency, ovariectomized (ovx) mice were treated with either IL-1 receptor antagonist (IL-lra), a competitive inhibitor of IL-1, TNF binding protein (TNFbp), an inhibitor of TNF, or the anti-IL-6 antibody (Ab) 20F3 for the first 2 wk after surgery. ovx increased the bone marrow cells secretion of IL-1 and TNF, but not IL-6, and the formation of TRAPpositive osteoclast-like multinucleated cells (MNCs) in bone marrow cultures treated with 1,25(OH)2D3. The increase in MNC formation induced by ovx was prevented by in vivo treatment with either 17/8 estradiol, IL-lra, TNFbp, or anti-IL-6 Ab. However, the percent change in MNC formation induced by the anti-IL-6 Ab was similar in ovx and shamoperated animals, whereas IL-lra and TNFbp were effective only in ovx mice. MNC formation was also decreased by in vitro treatment of bone marrow cultures with IL-lra and TNFbp, but not with anti-IL-6 Ab. Ovx also increased bone resorption in vivo and in vitro, as assessed by the urinary excretion of pyridinoline cross links and the formation of resorption pits, respectively. IL-lra, TNFbp and estrogen decreased bone resorption in vivo and in vitro whereas the anti-IL-6 Ab inhibited bone resorption in vitro but not in vivo. In conclusion, these data indicate that IL-1 and TNF play a direct role in mediating the effects of ovx on osteoclastogenesis and bone resorption. The data also suggest that IL-6 is not essential for increasing bone resorption in the early postovariectomy period. (J. Clin. Invest. 1994. 
Introduction
Postmenopausal osteoporosis is a disorder characterized by a progressive loss of bone tissue which begins after natural or surgical menopause and leads to the occurrence of spontaneous fractures (1) . Although estrogen deficiency is known to cause bone loss by stimulating the resorptive activity of mature osteo- clasts (OCs)' and the proliferation and differentiation of OC precursors (2) , the mechanism of these effects is still conjectural at best. One such mechanism may be a modulatory effect on the secretion of factors that are produced in the bone microenvironment and influence bone remodeling (2, 3) . Among these are IL-1 (4-6), , and tumor necrosis factor a and /3 (TNF) (10, 11) . IL-I and TNF promote bone resorption in vitro (4, 5, 12) and in vivo (13) (14) (15) (16) by activating mature OCs indirectly, via a primary effect on osteoblasts (15, 17) , and by stimulating the proliferation and differentiation of OC precursors (18, 19) . When bound to the 80-kD binding chain of the IL-6 receptor, IL-6 also increases OC formation from hemopoietic precursors (20) . However, IL-6 does not activate mature OCs (21) . As a result, IL-6 stimulates bone resorption only in systems rich in OC precursors, such as the mouse fetal metacarpals (22) . The multiple and potent effects of these factors on bone resorption and the discovery of estrogen receptors in stromal cells (23), osteoblasts (24,25) OCs (26, 27) , and macrophages (28) , suggest that estrogen may modulate bone resorption and osteoclastogenesis by regulating the release of cytokines in the bone microenvironment. Several lines of evidence support this hypothesis. First, the expression of IL-1 and IL-6 mRNA is increased in bone cells from postmenopausal women (29) . Second, previous observations of ours (30) (31) (32) and others (10, (33) (34) (35) demonstrate that both natural and surgical menopause are associated with an increased monocytic production of IL-1, IL-6, and TNF which is blocked by estrogen replacement. Third, the simultaneous inhibition of IL-1 and TNFa normalizes the bone resorption activity of monocyte supernatants obtained from postmenopausal women (36) . Fourth, the block of IL-1 and IL-6, prevents bone loss in ovariectomized (ovx) rats (37) and decreases OC formation in ovx mice (8) , respectively. However, in spite of these observations, the relative importance of each cytokine and the mechanism by which they control bone resorption and osteoclastogenesis remains to be elucidated because of the large number of factors involved and their overlapping effects on bone remodeling (7, 10) .
The recent discovery of specific cytokine antagonists has made it possible to block the activity of these factors for prolonged periods of time and to investigate the role of cytokines in many diseases (38) . Among these inhibitors are the IL-I inhibitor, IL-I receptor antagonist (IL-lra), and the TNF inhibitor, TNF binding protein (TNFbp). Human IL-Ira is a recombinant 17-kD protein which shares 26% sequence homology with IL-1,B (39, 40) . IL-Ira binds to IL-I receptors and competes with both IL-la and IL-1p3 without detectable IL-1 agonistic effects (41, 42) . TNFbp is a specific TNF inhibitor made of two molecules of the extracellular domain of the human type I TNF receptor added to both ends of a molecule of polyethylene glycol. TNFbp binds with equal affinity to TNFa and TNF/3.
In a recent study we have used IL-Ira to demonstrate that the functional block of IL-1 decreases bone loss and bone resorption in ovx rats (37) . In this study we have treated ovx mice with IL-Ira, TNFbp and the anti-IL-6 Ab 20F3 to investigate the role of IL-1, TNFa and IL-6 on the enhanced formation of osteoclast-like multinucleated cells (MNCs) and the increased bone resorption induced by estrogen deficiency.
Methods
Unless otherwise specified, reagents and media were from Sigma Chemical Co. (St. Louis MO).
Study protocol. Pyridinoline cross-links assay. The urinary excretion of pyridinoline cross-links, a marker of bone resorption (46) , was measured at the end of the treatment period in urine samples collected between 2:00 and 6:00 PM using an ELISA kit developed by Metra Biosystems (Palo Alto, CA) (47) . Briefly, 10 M1 urine sample and 150 ,ul of rabbit antipyridinoline antiserum were added to a pyridinoline-coated microplate and incubated overnight. After the plates were washed with PBS, 150
,ul of goat anti-rabbit IgG alkaline phosphatase conjugate was added to each well. The unbound conjugate was then removed by washing and the enzyme activity measured photometrically by adding an enzyme substrate and using a microplate reader at 405 nm. Results were expressed as nmol/mmol urinary creatinine, as measured by a standard colorimetric technique. The intra-and the interassay variation of this method are < 7 and < 10%, respectively (47).
Cytokine assays. To investigate the effect of ovx on the production of cytokines from bone marrow cells, additional groups of untreated and estrogen-treated mice were subjected to ovx or sham operation as described above and killed 2 wk after surgery. At time of death bone marrow cells were prepared as described above, seeded at 5 x 106 cells/ ml and cultured for 72 h. IL-1, IL-6, and TNF were measured in the bone marrow cell culture media collected at the end of the culture period. IL-I bioactivity was measured by assessing the increment in mitogen induced proliferation of the helper T cell DIO.G4.1 (DIO cells) as previously described (30, 31, 37) . The sensitivity of this assay was 1-10 pg/ml. The nature of the assayed material was confirmed as IL-1 by demonstrating inhibition of the conditioned medium effect on the D1O cells proliferation in the presence of 50 ng/ml IL-Ira. IL-6 was measured with a specific double site ELISA (Pharmingen, San Diego, CA). The sensitivity of this assay was 10 pg/ml. TNF was measured by a specific double-site ELISA previously described (48) , using antibodies (Pharmingen) which recognize both TNFa and TNF,l. The sensitivity of this assay was 25 pg/ml. Serum IL-Ira and TNFbp assays. Serum levels of IL-Ira were measured at 2 wk of treatment using a specific ELISA recently described (49) . The sensitivity of this assay is 8 pg/ml. The serum levels of TNFbp were estimated indirectly by a specific double-site ELISA (R& D Systems Inc. Minneapolis, MN) which recognizes the soluble human type I TNF receptor. The sensitivity of this assay is 10 pg/ml.
Assessment of serum neutralization activity. The presence of active IL-Ira in the serum of IL-Ira-treated mice was determined by assessing the serum obtained from ovx mice at the end of the treatment period against IL-l-3 augmentation of mitogen-induced proliferation of DIO cells, as previously described (37) . Briefly, mouse sera (12.5 /1) or ILlra (2.5 ng) were serially diluted (1:2) and added to DIO cells seeded in 96-wells plates. Recombinant (r) human IL-1,8 (7.5 pg) was then added to each well. This concentration of rIL-1f3 was selected because it induces 50% maximal augmentation in the DIO cell proliferation assay. At the end of a 3-d culture period the DIO cell proliferation was measured as previously described (37) . Results were expressed as percent change in D10 cell proliferation.
The presence of active TNFbp and anti-IL-6 Ab in the 2-wk serum of TNFbp-and 20F3 Ab-treated mice was assessed by measuring the ability of the sera to inhibit the binding of rTNFa and rIL-6 to immobi- 
Results
Effect of ovariectomy on the secretion of cytokines from cultured bone marrow cells. Mononuclear cells cultured in polystyrene plates with ordinary tissue culture media (which contains small amounts of LPS) express IL-1, IL-6, and TNF mRNA and secrete small quantities of cytokines (50) (51) (52) . In accordance with these published data, 2 wk after surgery, bone marrow cells from untreated sham-operated mice were found to secrete measurable amounts of IL-I bioactivity (which was neutralized by the addition of IL-Ira to the assay system), TNF and IL-6, into the 72-h culture medium (Table I) . Ovx increased significantly the production of IL-I and TNF, but not IL-6, as demonstrated by the finding of higher levels of IL-I and TNF in the culture media of cells from untreated ovx mice than in those from sham-operated or estrogen treated ovx animals (Table I).
Effect of ovx on osteoclast formation and bone resorption.
In preliminary studies (not shown) we have found that when bone marrow cells were cultured in presence of 10 nM 1,25(OH)2D3 TRAP-positive mononulear cells developed in the bone marrow cultures after 3-4 d of incubation. TRAP-positive MNCs which resorb bone and express the calcitonin receptor appeared on days 5-6 and reached a peak at day 7 ( Fig. 1, A-D) . The lack of 1,25(OH)2D3 during the first 4 d of culture did not prevent MNC formation. In contrast, the withdrawal of 1,25(OH)2D3 during the last 3 d of a 7-d culture prevented MNC formation, confirming the essential role of 1,25(OH)2D3 for the differentiation of MNCs precursors. MNC formation was proportional to the number of seeded cells with an optimal yield at 2.5-5 x 106 cells/cm2. Fig. 2 shows the effect of ovx on bone marrow cells and MNC formation. At time of death (2 wk after surgery) the number of bone marrow cells derived from untreated ovx mice was -1.5 fold higher than that derived from sham-operated mice. At the end of the 7-d-long culture, bone marrow preparations from ovx mice also had a higher numbers of MNCs than cultures from sham-operated mice. This difference was observed when the results were expressed either as MNCs/106 bone marrow cells or as MNCs/mouse. Fig. 2 also shows that the effects of ovx were completely prevented by estrogen treatment in vivo.
Time course experiments (not shown) revealed that the earliest time point at which the difference in production of MNCs between sham and ovx mice became significant was 10 d after surgery. The production of MNCs remained significantly higher in cultures from ovx mice than in those from sham-operated mice for 4 wk after surgery.
To investigate the effects of ovx on bone resorption in vivo, we measured the urinary excretion of pyridinoline cross-links (PYD), a new sensitive marker of resorption activity (46) . 2 wk after surgery PYD excretion was (Fig. 3 A) significantly higher in ovx than in sham-operated mice. This increase was completely prevented by estrogen treatment. We then assessed the ability of osteoclast-like cells to form resorption pits in vitro. For these experiments bone marrow cells were harvested 2 wk after ovx or sham operation, seeded on thin slices of human bone and cultured for 7 d. Cells were then removed and the resorption pits visualized by staining the bone slices with toluidine blue. Fig. 3 in a manner similar to fresh IL-Ira (Fig. 4) . Similarly, competition ELISA experiments demonstrated that the sera of TNFbpor anti-IL-6 Ab-treated mice decreased the binding of rTNFa and rIL-6 to the corresponding capture Ab in a manner similar to fresh TNFbp or fresh Ab 20F3. These data demonstrate that at 2 wk the sera of treated mice were able to neutralize the %t corresponding cytokine. Bone marrow cells were recovered at the end of the treatment period and cultured in presence of 10 nM 1,25(OH)2D3 for 7 d. Table II shows that the increase in the number of bone marrow cells associated with ovx was prevented by each of the + three cytokine inhibitors. Fig. 5 shows that the increase in MNC formation induced by ovx was blocked by all treatments. In these experiments the potency of IL-Ira was similar to that of TNFbp, and superior to that of IL-6. As a result, the IL-Ira and TNFbp treated groups produced a number of MNCs similar to that of sham control groups, whereas bone marrow cells from ovx mice treated with anti-IL-6 Ab formed significantly more MNCs than the corresponding sham control group. Treatment with both IL-Ira and TNFbp caused a further, although not significant, inhibition of MNC formation, thus suggesting that the effect of the two inhibitors is partially additive. Moreover, while IL-lra and TNFbp had no effects on MNC formation in sham-operated mice, the percent change in MNC formation induced by the anti-IL-6 Ab was similar in ovx and shamoperated animals, suggesting that the contribution of IL-6 to osteoclastogenesis does not increase with estrogen withdrawal.
To rule out the possibility that the effects of IL-Ira and TNFbp on MNC formation may result from an aspecific ref sponse to proteins, additional experiments were performed in which ovx and sham-operated mice were treated with 25 mg/ KgBW per day bovine serum albumin (BSA). These experiments revealed that BSA did not affect MNC formation (data not shown).
We then investigated whether the in vitro addition of the cytokine inhibitors to the bone marrow cultures from untreated mice decreases MNC formation. For these experiments bone marrow cells obtained from untreated ovx and sham-operated mice were cultured for 7 d as described in the methods. Fig. 6 shows that IL-Ira (5-50 tg/ml) and TNFbp (0.5-5.0 ,ug/ml) were equally potent in decreasing MNC formation in cultures derived from both ovx and sham-operated mice. In contrast, in vitro treatment with the anti-IL-6 Ab 20F3 ,ug/ml) or 17p3 estradiol (10-p-10-6 M) (not shown) had no effect.
To determine whether IL-1 and TNF are involved in the proliferation or the differentiation of OC precursors, additional expenments were performed in which bone marrow cultures from intact mice were treated with IL-Ira, TNFbp, or anti-IL-6 Ab for selected periods. The duration of the proliferative phase was determined in preliminary experiments which showed that MNC formation was completely blocked by treatment with 0. Effect of in vivo treatment with IL-Ira, TNFbp and anti-IL-6 Ab on in vivo and in vitro bone resorption. To investigate the effects of IL-Ira, TNFbp and anti-IL-6 Ab on OC activity, we investigated the effects of these inhibitors on bone resorption in vivo by measuring the urinary excretion of PYD. 2 wk after surgery PYD excretion was (Fig. 7 ) significantly higher in untreated ovx mice than in sham-operated mice. Treatment with IL-Ira and TNFbp decreased pyridinoline excretion in a manner similar to estrogen. In contrast, treatment with anti-IL-6 Ab had no effects. Treatment with each of the three cytokine inhibitors did not alter PYD excretion in sham-operated mice. These data demonstrate that IL-Ira and TNFbp prevent the effects of ovx on bone resorption in vivo.
We then assessed the impact of cytokine inhibition in vivo on bone resorption in vitro by measuring the ability of IL-Ira, TNFbp and anti-IL-6 Ab to decrease the excavation of resorption pits. These experiments (Fig. 8) confirmed the data shown in Fig. 3 B as they demonstrated that during the 7-d culture period bone marrow cells obtained from ovx mice excavated a larger bone area than cells from sham-operated mice. IL-1ra and TNFbp completely prevented the ovx-induced increase in the area resorbed by the OC-like cells. The area resorbed by cells obtained from ovx mice treated with these agents was, in fact, similar to that excavated by cells from control sham-operated mice. Unexpectedly, simultaneous treatment with IL-1ra and TNFbp was less effective, although not significantly, than treatment with TNFbp only. Treatment with anti-IL-6 Ab also decreased pit area, although cells from ovx mice treated with the anti-IL-6 Ab formed more abundant resorption pits than those from sham mice treated with control antibody. None of the three cytokine inhibitors decreased the excavation of resorption pits in sham-operated mice.
Since the magnitude of the inhibitory effect on in vitro bone resorption of each substance was similar to that on osteoclastogenesis, the data suggest that IL-1, IL-6, and TNF modulate bone resorption by regulating osteoclastogenesis, rather than the resorption activity of individual OCs.
Discussion
In this study we have investigated the effects of IL-Ira, TNFbp, and the anti-IL-6 Ab 20F3 on osteoclastogenesis and bone resorption. IL-Ira is a specific competitive inhibitor of IL-1 which does not possess IL-1 agonistic effects (54) . TNFbp is a divalent inhibitor of TNF which binds specifically and with equal affinity to both TNFa and TNF/3, and, at the dose used in this study, prevents endotoxin-induced lethality in mice (unpublished observations). The anti-IL-6 Ab 20F3 has been previously used with the same modalities as in this study, to neutralize IL-6 in vivo for up to 4 wk (8) . In agreement with these observations we have found that the serum of mice treated with anti-IL-6 Ab was capable of neutralizing rIL-6 in a manner similar to fresh anti-IL-6 Ab. In this study we have also found that the infusion of IL-Ira resulted in serum IL-lra levels 16 times higher than that required to block 45Ca release in vitro from mouse bone stimulated with 100 pg/ml of IL-1 (28) and that the injection of TNFbp resulted is serum type I TNF receptor levels 5-10 times higher than the amount of recombinant TNFa required to stimulate bone resorption in vitro (15) . Assays of cytokines in the culture media of bone marrow cells revealed that ovx is associated with an increased production of IL-1 and TNF, a finding in keeping with previous rat and human studies of ours and others (30, 31, 33, 34, 37, 55) but in contrast with those Hustmyer et al. (56) and Zarrabeitia et al. (57) who failed to detect a higher production of IL-1 and TNF in osteoporotic women. We also found that ovx was not associated with an increased bone marrow cell production of IL-6. This is agreement with the studies of Chaudhary et al. (8) who documented an increased production of IL-6 from bone marrow cells from mice killed 28 d after ovariectomy. Differences in assay techniques (bioassays vs ELISAs and IRMAs) and experimental design (samples obtained 14 vs 28 d after ovariectomy) are likely to account for these discrepancies. To investigate the role of IL-1, IL-6, and TNF in the increase in bone resorption induced by ovx, we examined the effects of the functional block of these three cytokines on MNCs maturation. Our data show that in ovx mice the proliferation and differentiation of MNCs precursors was blocked each of the three inhibitors, thus demonstrating that IL-1, IL-6, and TNF play a direct role in osteoclastogenesis. Although, the potency of IL-Ira was similar to that of TNFbp, and superior to that of IL-6, these data should be interpreted with caution, due to difference in size and structure between the anti-IL-6 antibody, IL-1ra, and TNFbp. Surprisingly, the effects of IL-Ira and TNFbp in ovx mice were scarcely additive, presumably because the in vivo experiments were conducted using maximally effective doses of each inhibitor. The complex effects of IL-1 and TNF on each other's synthesis and receptor expression (60) could also account for this observation. IL-Ira and TNFbp had no effects on sham-operated animals, indicating that these agents specifically block estrogen regulated MNC formation and activation. In contrast, treatment of with the anti-IL-6 Ab 20F3, carried out as described by Jilka et al. Poli et al. (61) in a study demonstrating that IL-6 deficient mice fail to lose bone in response to ovariectomy. Our findings are not directly comparable with those of Poli et al. because of the profound differences in the two experimental models. Postmenopausal osteoporosis results, in fact, from the impact of estrogen deficiency on a normally developed skeleton, a condition which can be replicated in normal mice by ovariectomy. In contrast, IL-6-deficient mice are characterized by bone modeling and remodeling defects which ensue during fetal development and lead to the formation of an altered mature skeleton.
Recently, we have reported that treatment with IL-1ra decreases bone loss and bone resorption in ovx rats (37) , thus demonstrating that IL-1 plays a direct, causal role in the bone loss induced by estrogen deficiency. In this study, we have investigated the mechanism of the effect of IL-1ra and demonstrated that IL-lra blocks the proliferation and differentiation of MNCs precursors. IL-I ra also decreased the urinary excretion of PYD and the formation of resorption pits. However, since the inhibitory effect on pit formation was proportional to that on MNC formation, the data indicate that the main effect of IL-Ira is not to decrease the resorptive activity of each OC, but rather to regulate the number of OC precursors which reach functional maturity. Our data also show that inhibition of TNF with TNFbp inhibits MNC formation on bone resorption in a manner similar to IL-Ira and estrogen. These data confirm earlier studies in vitro indicating a substantial functional overlap between IL-1 and TNF (52) .
Although the source and the cellular target of IL-I and TNF have not been investigated in this study, our working hypothesis is that estrogen deficiency increases the production of IL-1 and TNF from cells of the monocyte/macrophage lineage. These cytokines could, in tum, stimulate stromal cells to produce membrane-bound and soluble factors such as M-CSF and IL-11 which regulate the proliferation and differentiation of the hemopoietic MNC precursors (62) . This hypothesis is supported by studies which demonstrate the capacity of IL-1 and TNF to stimulate the stromal cell production of M-CSF and IL-i 1 (63) (64) (65) (66) and the essential role of the latter two factors in regulating the proliferation and differentiation of MNC progenitors (53, (66) (67) (68) (69) . Moreover, the recent study of Glowacki et al. (66) demonstrating that MNC precursors are the target of IL-6 suggests that IL-6 may also be one of the cytokines produced by stromal cells in response to IL-1 and TNFa, which regulates the early differentiation steps of the hemopoietic MNC precursors. According to this hypothesis, the effects of IL-6 would resemble those of IL-I1, which, interestingly, is also not regulated by estrogen (69) and uses gpl30 as a signal transducer (70) . Our data also demonstrate that IL-6 plays a role different from that of IL-1 and TNF in bone resorption. In particular, while in vivo inhibition of IL-1 and TNF blocked bone resorption in vitro and in vivo, treatment with the anti-IL-6 Ab decreased pit formation, but not PYD excretion. Since the regula- tory role of IL-6 is limited to the initial steps of the MNCs differentiation process (21) , it could be that the block of IL-6 in vivo is insufficient for preventing the complete maturation and activation of those cells which are "downstream" with respect to the IL-6-dependent steps (Fig. 9 ). According to this hypothesis, the lack of change in PYD excretion during the 2-wk-long treatment with anti-IL-6 Ab would reflect the maintenance of an unaltered pool of active, mature OCs. Conversely, the decreased pit formation observed with the IL-6 block is likely to reflect the decreased bone marrow content of OC precursors and the resulting decrease in the number of cells which reach functional maturity in vitro (62) . From this hypothesis one would predict that inhibition of IL-I and TNF blocked bone resorption in vivo and in vitro because these cytokines regulate early and late steps of the OC maturation process. Long term studies will be necessary to fully determine the role of IL-6 in bone resorption and to ascertain whether OC maturation and activation is maintained unaltered in conditions in which IL-6 is chronically blocked.
In conclusion, these data indicate that IL-1 and TNF play a direct role in mediating the effects of ovx on OC formation and bone resorption. The data also suggest that IL-6 is not essential for increasing bone resorption in the early post-ovx period.
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